CL2019000019A1 - Anticuerpos con baja inmunogenicidad y uso de los mismos - Google Patents

Anticuerpos con baja inmunogenicidad y uso de los mismos

Info

Publication number
CL2019000019A1
CL2019000019A1 CL2019000019A CL2019000019A CL2019000019A1 CL 2019000019 A1 CL2019000019 A1 CL 2019000019A1 CL 2019000019 A CL2019000019 A CL 2019000019A CL 2019000019 A CL2019000019 A CL 2019000019A CL 2019000019 A1 CL2019000019 A1 CL 2019000019A1
Authority
CL
Chile
Prior art keywords
antibodies
low immunogenicity
methods
antigen binding
binding fragments
Prior art date
Application number
CL2019000019A
Other languages
English (en)
Inventor
Kandasamy Hariharan
Jeonghoon Sun
Jeffrey C Johnson
Lawrence Dearth
Haralambos Hadjivassiliou
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CL2019000019A1 publication Critical patent/CL2019000019A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se proporcionan anticuerpos y fragmentos de unión al antígeno de estos con inmunogenicidad baja o nula en seres humanos y opcionalmente con características de fabricación deseables. También se proporcionan composiciones que comprenden dichos anticuerpos o fragmentos de unión al antígeno, métodos para utilizar dichos anticuerpos, y métodos para elaborar dichos anticuerpos.
CL2019000019A 2016-07-06 2019-01-04 Anticuerpos con baja inmunogenicidad y uso de los mismos CL2019000019A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662359150P 2016-07-06 2016-07-06

Publications (1)

Publication Number Publication Date
CL2019000019A1 true CL2019000019A1 (es) 2019-06-28

Family

ID=60913146

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000019A CL2019000019A1 (es) 2016-07-06 2019-01-04 Anticuerpos con baja inmunogenicidad y uso de los mismos

Country Status (19)

Country Link
US (1) US11427632B2 (es)
EP (1) EP3481862A4 (es)
JP (1) JP7120989B2 (es)
KR (1) KR20190035737A (es)
CN (1) CN109689684B (es)
AR (1) AR108975A1 (es)
AU (1) AU2017292752B2 (es)
BR (1) BR112019000166A2 (es)
CA (1) CA3029977A1 (es)
CL (1) CL2019000019A1 (es)
CO (1) CO2019001112A2 (es)
EA (1) EA201990218A1 (es)
EC (1) ECSP19008417A (es)
IL (1) IL264009A (es)
MX (1) MX2019000172A (es)
SG (1) SG11201811788SA (es)
TW (1) TW201811824A (es)
WO (1) WO2018009499A1 (es)
ZA (1) ZA201900070B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7262440B2 (ja) 2017-08-02 2023-04-21 フェインズ セラピューティクス，インコーポレーテッド 抗ｃｄ４７抗体及びその使用
KR102115300B1 (ko) * 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
TW202104260A (zh) 2019-04-05 2021-02-01 美商西建公司 腫瘤選擇性結合ｃｄ４７之抗體之工程
US20200400662A1 (en) 2019-06-07 2020-12-24 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
US20230365681A1 (en) 2020-10-07 2023-11-16 Celgene Corporation Bispecific antibody treatment of lymphoid malignant neoplasm conditions
US20220196651A1 (en) 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
GB9026912D0 (en) 1990-12-11 1991-01-30 Wessex Instrumentation Limited Reaction detection equipment
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ES2176484T3 (es) * 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
AU2004229501B2 (en) * 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US20060228350A1 (en) 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
US7354854B2 (en) 2005-05-24 2008-04-08 Texas Instruments Incorporated Nickel silicide method and structure
MX2007014565A (es) 2005-06-01 2008-02-11 Micromet Ag Anticuerpos anti-il2.
US8101727B2 (en) 2006-03-30 2012-01-24 Novartis Ag Compositions and methods of use for antibodies of c-Met
EP2121756A4 (en) * 2006-12-20 2011-08-31 Mmrglobal Inc ANTIBODIES AND PROCESS FOR THEIR PREPARATION AND USE
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
KR101721187B1 (ko) 2009-12-23 2017-03-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역원성의 감소 방법
LT2536764T (lt) 2010-02-18 2018-10-25 Ose Immunotherapeutics Anti-cd28 humanizuoti antikūnai
KR102100388B1 (ko) * 2012-02-06 2020-04-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
EP2859017B1 (en) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP2890402B1 (en) 2012-08-31 2019-04-17 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
NZ710695A (en) 2013-02-06 2020-05-29 Inhibrx Inc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
WO2016073906A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
EP3221358B1 (en) 2014-11-18 2021-07-21 Janssen Pharmaceutica, N.V. Cd47 antibodies, methods, and uses
MX391051B (es) * 2014-12-30 2025-03-21 Celgene Corp Anticuerpos anti-cd47 y usos de los mismos.
WO2017053423A1 (en) * 2015-09-21 2017-03-30 Erasmus University Medical Center Anti-cd47 antibodies and methods of use

Also Published As

Publication number Publication date
WO2018009499A1 (en) 2018-01-11
US11427632B2 (en) 2022-08-30
KR20190035737A (ko) 2019-04-03
AU2017292752A1 (en) 2019-01-24
EP3481862A1 (en) 2019-05-15
TW201811824A (zh) 2018-04-01
ZA201900070B (en) 2023-08-30
JP7120989B2 (ja) 2022-08-17
SG11201811788SA (en) 2019-01-30
CN109689684B (zh) 2022-09-23
EA201990218A1 (ru) 2019-07-31
CO2019001112A2 (es) 2019-02-19
EP3481862A4 (en) 2020-08-12
ECSP19008417A (es) 2019-02-28
AR108975A1 (es) 2018-10-17
CA3029977A1 (en) 2018-01-11
US20190241654A1 (en) 2019-08-08
JP2019524087A (ja) 2019-09-05
IL264009A (en) 2019-01-31
BR112019000166A2 (pt) 2019-10-01
CN109689684A (zh) 2019-04-26
AU2017292752B2 (en) 2023-07-27
MX2019000172A (es) 2019-09-26

Similar Documents

Publication Publication Date Title
CL2019000019A1 (es) Anticuerpos con baja inmunogenicidad y uso de los mismos
ECSP18095014A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
UY40829A (es) Anticuerpos anti-phf-tau y sus usos
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
CO2018012699A2 (es) Anticuerpos anti-cd40 y sus usos
ECSP18023386A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
MX383464B (es) Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
MX2018012076A (es) Composiciones y anticuerpos anti proteina 3 que contiene inmunoglobulina de linfocitos t y el dominio de mucina (tim-3).
MX2019004690A (es) Constructos de anticuerpos.
GT201700102A (es) Conjugados de anticuerpo-fármaco
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
CR20170262A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
UY37279A (es) Anticuerpos tgf-beta y fragmentos de unión de los mismos
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX2015016627A (es) Vacuna para la malaria.
BR112017023131A2 (pt) anticorpos anti- fcrn
MX382409B (es) Variantes de proteinas de unión al factor h y métodos de uso de estas.
MX2018013222A (es) Anticuerpos de interferon beta y usos de los mismos.
CY1119912T1 (el) Αντιγονα και συνδυασμοι αντιγονων pseudomonas
AR095939A1 (es) Vacuna contra garrapatas rhipicephalus
AR115987A1 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
AR115992A2 (es) Proteínas de unión a antígeno que activan el receptor de leptina